SGLT2 Inhibitors vs GLP-1 Receptor Agonists: What Cardiovascular Evidence Shows
A 2026 network meta-analysis found SGLT2 inhibitors more consistently reduced heart failure hospitalization, while mortality comparisons remained uncertain and empagliflozin’s arrhythmia signal requires confirmation.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.